<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NEVIRAPINE </span><br/>(ne-vir'a-peen)<br/><span class="topboxtradename">Viramune<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">nonnucleoside reverse transcriptase inhibitor (nnrti)</span><br/><b>Prototype: </b>Efavirenz<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg tablets; 10 mg/mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Nonnucleoside reverse transcriptase inhibitor (<small>NNRI</small>) of HIV-1. Binds directly to reverse transcriptase and blocks RNA- and DNA-dependent polymerase activities.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents replication of the HIV-1 virus. Does not inhibit HIV-2 reverse transcriptase and DNA polymerases such as alpha, beta,
         gamma, and delta polymerases. Resistant strains appear rapidly.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with nucleoside analogs for treatment of HIV.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to nevirapine; hormonal contraceptives; pregnancy (category C), neonates; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver or renal disease, hepatitis B or C; CNS disorders.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg once daily for first 14 d, then increase to 200 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 120 mg/m<sup>2</sup> q.d. <small>x</small> 14 d, then increase q12h, if tolerated, to 120200 mg/m<sup>2</sup> q12h (max: 200 mg/dose)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Reinitiate with 200 mg/d for 14 d, then increase to b.i.d. dosing, when dosing is interrupted for &gt;7 d.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, paresthesia, myalgia. <span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Nausea, diarrhea, abdominal pain, hepatitis, increased liver function tests, <span class="speceff-life">hepatotoxicity</span> (including <span class="speceff-life">fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure</span>, especially with long-term use).  <span class="typehead">Hematologic:</span> Anemia, neutropenia. <span class="typehead">Skin:</span> <span class="speceff-common">Rash,</span> <span class="speceff-life">Stevens-Johnson syndrome</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease plasma concentrations of <span class="classification">protease inhibitors</span>, <span class="classification">oral contraceptives</span>; may decrease <b>methadone</b> levels inducing opiate withdrawal. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may decrease antiretroviral activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> 4h. <span class="typehead">Distribution:</span> 60% protein bound, crosses placenta, distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P45O-3A (CYP3A). <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 2540 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline and periodic liver and kidney function tests, routine blood chemistry, and CBC.</li>
<li>Monitor weight, temperature, respiratory status with chest x-ray throughout therapy.</li>
<li>Monitor carefully, especially during first 6 wk of therapy, for severe rash (with or without fever, blistering, oral lesions,
            conjunctivitis, swelling, joint aches, or general malaise).
         </li>
<li>Withhold drug and notify physician if rash develops or liver function tests are abnormal.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn about common adverse effects.</li>
<li>Withhold drug and notify physician if severe rash appears.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known. There is a high potential for
            drowsiness and fatigue.
         </li>
<li>Use or add barrier contraceptive if using hormonal contraceptive.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>